WPD Pharmaceuticals Inc.
WPDPF
$0.00
$0.000.00%
| Weiss Ratings | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | D | |||
| Rating Factors | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 38.84 | |||
| Price History | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -100.00% | |||
| 60-Day Total Return | -100.00% | |||
| 90-Day Total Return | -100.00% | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -100.00% | |||
| 3-Year Total Return | -100.00% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -99.90% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jan 08, 2024 | |||
| 52-Week High Price (Date) | Jul 08, 2024 | |||
| Valuation | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 413.94K | |||
| Enterprise Value | 655.00K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -102.72% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -2.98 | |||
| Enterprise Value/EBIT | -2.91 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.79M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 700 – 595 Burrard Street Vancouver, BC V7X 1S8 | |||
| Website | www.wpdpharmaceuticals.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -69.13% | |||
| Return on Equity | -- | |||
| Income Statement | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -221.50K | |||
| EBIT (TTM) | -226.40K | |||
| Net Income (TTM) | -104.80K | |||
| Net Income Avl. to Common (TTM) | -104.80K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 76.24% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | 80.00% | |||
| Balance Sheet | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.20K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 35.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -493.70K | |||
| Current Ratio (Q) | 0.080 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 199.60K | |||
| Total Current Liabilities (Q) | 444.20K | |||
| Total Debt (Q) | 249.00K | |||
| Total Liabilities (Q) | 693.20K | |||
| Total Common Equity (Q) | -493.70K | |||
| Cash Flow | WPDPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -24.50K | |||
| Net Change in Cash (TTM) | -162.10K | |||
| Levered Free Cash Flow (TTM) | -122.80K | |||
| Cash from Operations (TTM) | -137.60K | |||
